报价延迟最少15分钟:2025/07/22 03:05 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.95 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.75/-2.24
|
|
企业价值
692.77M
|
| 资产负债 |
|
每股账面净值
2.95
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/22 03:05 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD). |
